---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-005219"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:56:42.465742+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotechnologies Q4 revenue +26% to $37.9M; CFO Chad Cohen resigns, interim CFO appointed

## Summary
- Q4 2021 revenue $37.9M (+26% YoY); net loss $61.4M (vs $44.6M). Full year revenue $154.3M (+57%); net loss $207.3M.
- Sequencing revenue Q4 $23.1M (+81% YoY); clonoSEQ clinical tests Q4 6,356 (+41%), full year 22,516 (+48%).
- Development revenue Q4 $14.9M (-15% YoY); cash, equivalents and marketable securities $570.2M at Dec 31, 2021.
- CFO Chad Cohen resigned effective Feb 15, 2022; Kyle Piskel appointed interim CFO.
- Genentech selected TCR candidate targeting shared cancer neoantigen; T-Detect COVID EUA with over 30,000 tests ordered.

## SEC filing metadata
- accession: 0001564590-22-005219
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005219/0001564590-22-005219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005219/adpt-8k_20220215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-005219
- JSON: https://secwatch.observer/filing/0001564590-22-005219.json
- Plain text: https://secwatch.observer/filing/0001564590-22-005219.txt

## Key facts
- Executive change
  Kyle Piskel was appointed as Interim Chief Financial Officer at Adaptive Biotechnologies Corp.
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: the Board of Directors of the Company appointed Mr. Kyle Piskel, the Company’s Principal Accounting Officer, as interim Chief Financial Officer effective concurrent with Mr. Cohen’s resignation
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005219/0001564590-22-005219-index.htm
- Executive change
  Chad Cohen resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: the Company’s Chief Financial Officer, Mr. Chad Cohen, is resigning effective February 15, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1478320/000156459022005219/0001564590-22-005219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.